LifeMD (LFMD) Q3 2026 earnings summary

Executive summary

• Q3 revenue was $44.6M, down 7% YoY and below guidance; delayed branded GLP-1 fulfillment and reduced marketing weighed on results.

• Adjusted EBITDA loss was $0.41M, improved $3.1M sequentially; active subscribers grew 13% YoY to 349,744.

• FY 2026 revenue and Adjusted EBITDA outlook was lowered; pharmacy fulfillment, enterprise distribution, and cost reductions underpin the growth plan.

Financial highlights

• Q3 revenue was $44.6M versus $47.7M a year ago and below the $48M–$51M guidance range; gross profit was $36.4M versus $40.7M.

• Gross margin was 81.51% versus 85.20% a year ago and ~89% in Q2.

• Net loss attributable to common stockholders was $5.25M, or $0.11/share, versus $4.67M, or $0.10/share, in Q3 2025.

• Adjusted EBITDA was a $0.41M loss versus $2.79M of income in Q3 2025 and a $3.5M loss in Q2 2026.

• Selling and marketing expense was $18.5M, down 34% QoQ and 18% YoY; G&A was $14.7M, up 6% YoY.

Outlook and guidance

• Q4 guidance: revenue of $46M–$49M and Adjusted EBITDA loss of $2M–$4M; excludes AT&T, broader enterprise, and new pharmacy products.

• FY 2026 revenue guidance was cut to $188M–$191M from $205.5M–$212.5M; Adjusted EBITDA guidance shifted to a $10.6M–$12.6M loss from breakeven to a $6M loss.

• 2027 patient and revenue growth was expected to be ~30% on roughly current fixed overhead; more specific guidance was planned for early Q1.

• Operating expense reduction target is at least 25% from Q1 2026 to Q1 2027, excluding working marketing spend.